
You Don't Want to Know Where Scientists Just Found 27 Million Tons of Plastic
Researchers from the Royal Netherlands Institute for Sea Research (NIOZ) and Utrecht University claim to be the first to provide a real estimate of ocean-polluting nanoplastics. Their research indicates that the North Atlantic Ocean alone hosts 27 million tons of floating plastic particles less than 1 micrometer (μm) in size.
'Plastic pollution of the marine realm is widespread, with most scientific attention given to macroplastics and microplastics. By contrast, ocean nanoplastics (<1 μm) remain largely unquantified, leaving gaps in our understanding of the mass budget of this plastic size class,' they explained in a study published earlier this month in the journal Nature. 'Our findings suggest that nanoplastics comprise the dominant fraction of marine plastic pollution.'
To reach these conclusions, Utrecht graduate student and study co-author Sophie ten Hietbrink collected water samples from 12 locations while working aboard a research vessel traveling from the Azores to the continental shelf of Europe. She filtered the samples of anything larger than one micrometer and conducted a molecular analysis on what was left behind. The team then extrapolated its results to the entire North Atlantic Ocean.
27 million tons is 'a shocking amount,' Ten Hietbrink said in a NIOZ statement. 'But with this we do have an important answer to the paradox of the missing plastic.' Namely, that a large part of it is floating in our oceans, invisible to the naked eye.
Unfortunately, there are a number of ways nanoparticles can end up in the oceans. While some likely arrive via rivers, others fall out of the sky with rain or on their own as 'dry deposition.' (Yes, we've even found plastic pollution in the sky). Nanoparticles can also form when large pieces of plastic already in the ocean are broken down by waves and/or sunlight, according to the researchers. The question now is how this pollution is impacting the world and its creatures—including us.
'It is already known that nanoplastics can penetrate deep into our bodies. They are even found in brain tissue. Now that we know they are so ubiquitous in the oceans, it's also obvious that they penetrate the entire ecosystem; from bacteria and other microorganisms to fish and top predators like humans,' said Helge Niemann, a geochemist at NIOZ and another co-author of the study. 'How that pollution affects the ecosystem needs further investigation.'
The missing plastic paradox, however, is not completely solved, because not all plastics were represented in the samples. The team didn't find polyethylene or polypropylene, for example.
'It may well be that those were masked by other molecules in the study. We also want to know if nanoplastics are as abundant in the other oceans. It is to be feared that they do, but that remains to be proven,' Niemann added. 'The nanoplastics that are there, can never be cleaned up. So an important message from this research is that we should at least prevent the further pollution of our environment with plastics.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
EnduroSat and WISeSat.Space Partner to Deliver Quantum-Resilient Secure IoT Nanosatellite Infrastructure
FOR IMMEDIATE RELEASE EnduroSat and Partner to Deliver Quantum-Resilient Secure IoT Nanosatellite Infrastructure Sofia, Bulgaria & Geneva, Switzerland – July 28, 2025 – WISeKey International Holding AG (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, via its subsidiary AG, a company that focuses on space technology for secure satellite communication, specifically for IoT applications, and EnduroSat, a leading provider of software-flexible satellites, as part of their strategy to diversify partners in the industry, are pleased to announce the signing of a Memorandum of Understanding (MoU) to establish a framework aimed at achieving a strategic partnership to extend the development and deployment of ultra-secure, quantum-resilient nanosatellite systems for Internet of Things (IoT) applications. The cooperation targets the integration of SEALSQ secure elements, such as the VaultIC292, VaultIC408, and QS7001, into satellite payloads and ground-level endpoints. These components enable strong hardware-based security and digital identity protection, ensuring encrypted communications and trusted authentication across the IoT satellite network. The project aims to implement post-quantum cryptographic (PQC) algorithms, aligned with NIST recommendations such as CRYSTALS-Kyber and CRYSTALS-Dilithium, to safeguard against future quantum computing threats. WISeSat will provide the PQC algorithmic stack and support, while EnduroSat will incorporate these into its satellite and communication platform. EnduroSat brings its expertise in modular satellite design, in-orbit validation, and scalable deployment systems. It will lead the physical integration of SEALSQ secure components into next-generation satellite buses and contribute to the overall mission architecture. WISeSat will support cryptographic integration and field engineering resources, ensuring that each system meets high-security and resilience benchmarks. The partnership further outlines the future integration of post-quantum cryptographic solutions and secure elements into both EnduroSat and WISeSat satellite infrastructures. EnduroSat will also support the design and deployment of WISeSat's future missions, ensuring compliance with defined security and performance requirements. This collaboration builds on WISeSat's successful deployment of its new-generation PQC-ready nanosatellite in December 2025 and EnduroSat's proven record of delivering more than 60+ satellites to orbit for institutional, scientific, and commercial customers. The resulting architecture will offer scalable, tamper-proof IoT connectivity services from Low Earth Orbit (LEO), critical for use-cases in logistics, critical infrastructure, defense, and environmental monitoring. 'This partnership with EnduroSat marks a significant step forward in our mission to deliver quantum-resilient, end-to-end secure satellite infrastructure,' said Carlos Moreira, Founder and CEO of WISeKey. 'By integrating SEALSQ's advanced secure elements into the expanding WISeSat constellation, we are building a tamper-proof communications backbone in space. Together with EnduroSat's modular satellite technology, we are enabling scalable and ultra-secure IoT connectivity services from Low Earth Orbit—critical for securing data and infrastructure in the quantum era.' 'We are excited to initiate this partnership,' said Raycho Raychev, founder & CEO of EnduroSat. 'We hope to accelerate the introduction and establishment of much stronger encryption capabilities into the satellite industry.' About AG is pioneering a transformative approach to IoT connectivity and climate change monitoring through its innovative satellite constellation. By providing cost-effective, secure, and global IoT connectivity, WISeSat is enabling a wide range of applications that support environmental monitoring, disaster management, and sustainable practices. The integration of satellite data with advanced climate models holds great promise for enhancing our understanding of climate change and developing effective strategies to combat its impacts. As the world continues to grapple with the challenges of climate change, initiatives like WISeSat's IoT satellite constellation are essential for creating a more resilient and sustainable future. About WISeKeyWISeKey International Holding Ltd ('WISeKey', SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) Corp which focuses on trusted blockchain NFTs and operates the marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN platform. Each subsidiary contributes to WISeKey's mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using Blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. The company's semiconductors generate valuable Big Data that, when analyzed with AI, enable predictive equipment failure prevention. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, Blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey's strategic direction and its subsidiary companies, please visit About EnduroSatEnduroSat is a space infrastructure builder that engineers, builds, and operates exceptional satellites. The company streamlines space missions in LEO and beyond, handling every step from mission design to launch and operations. EnduroSat serves more than 360 customers globally and employs more than 230 space professionals across 6 locations worldwide. For more information, visit DisclaimerThis communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act ('FinSA'), the FinSa's predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey. Press and Investor Contacts WISeKey International Holding LtdCompany Contact: Carlos MoreiraChairman & CEOTel: +41 22 594 3000info@ WISeKey Investor Relations (US) The Equity Group CatiTel: +1 212 836-9611 lcati@ ENDUROSAT EADCompany Contact: Raycho RaychevFounder & CEOinfo@
Yahoo
an hour ago
- Yahoo
Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
First patient dosed in global pivotal clinical trial program for late infantile/juvenile onset NPC and GM1/GM2 gangliosidoses. Both studies are part of Azafaros' mission to develop treatments for the unmet need of patients with rare lysosomal storage disorders The news follows the company's recent successful €132M Series B financing, aimed at supporting the rapid development of nizubaglustat and the expansion of Azafaros' pipeline to other indications LEIDEN, Netherlands, July 28, 2025--(BUSINESS WIRE)--Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that the first patient has been dosed in the company's pivotal, multicenter Phase 3 clinical program to evaluate the safety and efficacy of the company's lead asset, nizubaglustat, in patients with Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses. The initiation of the two Phase 3 studies (NCT07054515) represents a major milestone in Azafaros' commitment to addressing the urgent unmet medical needs of children affected by these devastating neurodegenerative disorders. The Phase 3 program consists of two studies targeting the late-infantile and juvenile-onset forms of NPC, and GM1/GM2 gangliosidoses. The studies aim to assess the potential of nizubaglustat to alter disease progression and improve functional outcomes in these patient populations. Today's news follows the recent, successful completion of an oversubscribed series B financing, raising €132M to support the acceleration of nizubaglustat and the expansion of the company's pipeline to other indications. "The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, families, clinicians, and advocacy groups who are partnering with us to advance this promising therapy." About the NAVIGATE trial The two 18-month randomized 2 to 1, double-blind, placebo-controlled trials will recruit patients at approximately 35 sites across 15 countries worldwide, including in the US, Europe and Latin America. The studies are expected to enroll around 70 patients. The primary endpoint for both trials is the change from baseline to Month 18 in the Scale for the Assessment and Rating of Ataxia (SARA), with both total and functional SARA scores evaluated. For more information on the Phase 3 program, please visit To enquire about trial participation, email: medinfo@ (if a professional) or patientadvocacy@ (if a patient or caregiver). To protect privacy, avoid including identifying information in the initial message. About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting, neurological, lysosomal storage disorder, caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital. View source version on Contacts For further information: Azafaros info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
Brains Aged Faster In 2021–2022: What Did The Pandemic Do To Us?
A new study suggests that the pandemic may have had a significant impact on our brains, whether or not we contracted COVID-19. Leveraging an extensive database of brain scans, British researchers say that people's brains showed accelerated aging during 2021 and 2022, including signs of shrinkage. While people who were infected with COVID also showed cognitive decline, like slower processing speed, the study was notable because it said even the non-infected were likely to experience harm to their brain. While the study did not delve into the exact causes of the accelerated aging, the study's first author, Ali-Reza Mohammadi-Nejad, a neuroimaging researcher at the University of Nottingham, theorizes that it may have been the result of stress and other factors. 'But it is likely that the cumulative experience of the pandemic—including psychological stress, social isolation, disruptions in daily life, reduced activity and wellness—contributed to the observed changes… In this sense, the pandemic period itself appears to have left a mark on our brains, even in the absence of infection,' said Mohammadi-Nejad, per NBC. The researchers found that males and 'those from more socioeconomically deprived backgrounds' experienced the most significant brain aging. Overall, the pandemic was thought to be linked to a 5.5-month acceleration in the aging process. This is not the first time researchers have reached similar conclusions. Last year, a previous study found that teenagers experienced dramatic brain aging during the pandemic. Notably, the study suggested that girls' brains aged 4.2 years faster and boys' brains aged 1.3 years faster, on average. The latest study does not indicate whether the structural changes identified in individuals who have never contracted COVID will result in any noticeable changes in brain function. Nor does the study confirm whether the physical changes will persist over the long term, says Adam Brickman, a professor of neuropsychology at Columbia University Vagelos College of Physicians and Surgeons, who was not involved in the study.